Related Experiment Video
Updated: Jun 3, 2026
Tissue Engineering by Intrinsic Vascularization in an In Vivo Tissue Engineering Chamber
Published on: May 30, 2016
[Cell sources for cardiovascular tissue engineering]
C Klopsch1, P Donndorf, A Kaminski
1Referenz- und Translationszentrum für kardiale Stammzelltherapie, Universität Rostock, Rostock, Germany.
Insights
Stem cell therapy shows promise for heart disease regeneration using various stem cell types. Fetal and adult stem cells offer safety and support for cardiovascular tissue engineering, advancing towards lab-grown hearts.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Stem Cell Biology
Context:
- Congenital and acquired heart diseases require novel regenerative strategies.
- Tissue engineering aims to create functional cardiovascular structures.
- Advances in stem cell biology offer potential therapeutic avenues.
Purpose:
- To review stem cell sources for cardiovascular tissue engineering.
- To evaluate the potency and safety of different stem cell types.
- To discuss medical and ethical considerations of stem cell applications in cardiology.
Summary:
- Embryonic stem cells and induced pluripotent stem cells can generate diverse cardiovascular lineages.
- Fetal and adult stem cells, including cardiac stem cells and myoblasts, exhibit limited differentiation but potent paracrine effects.
- Vascular, valvular, and myocardial tissues have been engineered, progressing towards a functional autologous heart.
Impact:
- Stem cell therapy holds significant potential for treating heart diseases.
- Understanding stem cell potency and safety is crucial for clinical translation.
- This review provides insights into the future of cardiac regenerative medicine and tissue engineering.
Abstract:
Numerous studies have confirmed that stem cell therapy has significant potential for the regeneration of congenital and acquired heart diseases. The utilization of embryonic stem cells and induced pluripotent stem cells promises a possible generation and regeneration of all cardiovascular structures. On the one hand fetal and adult stem cells, e.g. endothelial progenitors, mesenchymal, hematopoietic, cardiac stem cells and myoblasts, possess limited potential for multilinear differentiation. On the other hand these cells have high paracrin activity and support with well-confirmed safety the reconstruction and formation of cardiovascular structures. On the visionary track towards an autonomously functioning autologous heart generated by tissue engineering, vascular, valvular and myocardial tissues have already been successfully created. This manuscript describes the possible stem cell sources for cardiovascular tissue engineering and evaluates their potency and safety from a medical and ethical point of view employing the data from systematic reviews (Medline database) and own investigations.
